Kite Pharma, a subsidiary of Gilead Sciences, and Daiichi Sankyo have received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for their Yescarta (axicabtagene ciloleucel) for initial treatment of relapsed/refractory large B-cell lymphoma (LBCL). Yescarta, a chimeric antigen receptor (CAR) T-cell therapy, is used only in patients who have not received a […]
Kite, an arm of Gilead Sciences, has agreed to acquire Tmunity Therapeutics, a Philadelphia-based clinical-stage biotech company focused on next-generation CAR T-therapies and technologies, for an undisclosed amount. Under the agreement, Kite will acquire all the shares of Tmunity Therapeutics, which it already doesn’t own. The acquisition aligns with Kite’s current in-house cell therapy research […]
Arcellx, a US-based clinical-stage biotechnology company, and Kite, a Gilead company, are partnering to co-develop and co-commercialize the former’s CART-ddBCMA, a late-stage product candidate. CART-ddBCMA, currently in phase 2 clinical development, is intended for the treatment of patients with relapsed or refractory multiple myeloma. Arcellx and Kite will share development, clinical trial, and commercialization costs […]
US biopharma company Gilead Sciences has named Christi L. Shaw as the new chief executive officer of its subsidiary Kite, a California-based cell therapy company, which the former acquired for about $11.9 billion in 2017. Christi L. Shaw, who will also become a member of the senior leadership team of Gilead Sciences, is said to […]
Kite Pharma has clinched the US FDA approval for its Car T therapy Yescarta (axicabtagene ciloleucel) for treating a type of lymphatic cancer in patients who have no more treatment options left and are staring at a dire prognosis.
In a significant development for lymphoma treatment, Kite Pharma, a subsidiary of Gilead Sciences, has received approval from the U.S. Food and Drug Administration (FDA) for its chimeric antigen receptor T cell (CAR T) therapy, Yescarta (axicabtagene ciloleucel). This new therapy is now approved for adult patients in the United States with relapsed or refractory […]